Adjuvant stereotactic body radiotherapy for resected pancreatic adenocarcinoma with close or positive margins.
OBJECTIVE
The aim of this study was to evaluate the role of stereotactic body radiotherapy (SBRT) as adjuvant therapy for resected pancreatic adenocarcinoma with close or positive margins.


METHODS
Between September 2006 and January 2010, 24 patients were treated with adjuvant SBRT following surgical resection. Eight (33.3%) patients had close margins of 1-2.5 mm to the retroperitoneal, vascular structures, and periduodenal adipose tissue. Sixteen (66.7%) patients had positive margins at retroperitoneal margin and vascular structures. Twenty-three patients received 24 Gy (20-24 Gy) in one fraction, and one had 30 Gy in three fractions. The median target volume was 11 cc (4.5-30 cc). Eighteen patients were treated with the Cyberknife® Robotic Radiosurgery System and six patients were treated with Trilogy™ intensity-modulated radiosurgery. Kaplan-Meier survival analyses were used to estimate freedom-from-local-progression (FFLP), and overall survival (OS) rates. PET/CT or CT was used to monitor disease recurrence following SBRT.


RESULTS
The median follow-up for all patients was 12.5 months (1.4-39.5 months), and among surviving patients it was 16.3 months (2-39.5 months). The FFLP rates at 6 months, 1 and 2 years were 94.7%, 66%, and 44%, respectively. Overall, FFLP was achieved in seven (87.5%) patients with close margins, and 10 (62.5%) with positive margins. After SBRT, 19 patients resumed or started a 6-month course of gemcitabine-based chemotherapy at a median interval of 18 days (range, 9-31 days) post-SBRT. The median OS was 26.7 months and the 1- and 2-year OS rates were 80.4% and 57.2%, respectively. Of the 24 patients, 12 (50%) developed distant metastases of whom two (25%) had close margins and 10 (62.5%) had positive margins. Ten patients (41.7%) were free of progression at last follow-up (range, 3-39.5 months). Three patients (12.5%) had grade 1-2 acute GI toxicities, and two patients (8.3%) had grade 1 and 2 late toxicities. No patients experienced grade 3 or 4 toxicity, including bowel perforation, secondary to SBRT.


CONCLUSIONS
Our data suggest that adjuvant SBRT for resected pancreatic cancer can be achieved with minimal toxicity. This shorter treatment course allowed initiation of systemic chemotherapy shortly after the completion of SBRT.
Rwigema
Jean-Claude M
JC
Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Heron
Dwight E
DE
Parikh
Simul D
SD
Zeh
Herbert J
HJ
Moser
James A
JA
Bahary
Nathan
N
Ashby
Karlotta
K
Burton
Steven A
SA
D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D016634:Radiosurgery / Q000009:adverse effects
Br J Surg. 2000 Jul;87(7):883-9
10931023
Ann Surg. 2001 Dec;234(6):758-68
11729382
Cancer. 2009 Feb 1;115(3):665-72
19117351
N Engl J Med. 2004 Mar 18;350(12):1200-10
15028824
Cancer. 1976 Mar;37(3):1519-24
1260670
Lancet. 2001 Nov 10;358(9293):1576-85
11716884
Am J Clin Oncol. 2011 Feb;34(1):63-9
20308870
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):839-44
19647950
Am J Clin Oncol. 2010 Feb;33(1):101-6
19636239
Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1493-500
19464819
BMC Cancer. 2008 Jan 14;8:5
18194510
Ann Surg Oncol. 2006 Aug;13(8):1035-46
16865597
Ann Surg. 2006 Jul;244(1):10-5
16794383
Am J Clin Oncol. 2011 Aug;34(4):372-9
20859194
Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):735-42
20171803
Br J Surg. 2004 May;91(5):586-94
15122610
Ann Surg. 2005 Dec;242(6):781-8, discussion 788-90
16327488
World J Surg. 2003 Mar;27(3):324-9
12607060
JOP. 2008 Mar 08;9(2):99-132
18326920
Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3
7794076
Am J Clin Oncol. 2010 Jun;33(3):286-93
19875950
J Gastrointest Surg. 2006 Nov;10(9):1199-210; discussion 1210-1
17114007
Cancer. 1990 Jul 1;66(1):56-61
2354408
J Clin Oncol. 2009 Jun 10;27(17):2855-62
19398572
J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79
11307091
J Natl Cancer Inst. 1988 Jul 20;80(10):751-5
2898536
Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1017-21
15001240
Lancet. 2004 Mar 27;363(9414):1049-57
15051286
Br J Cancer. 2005 Apr 25;92(8):1372-81
15812554
JAMA. 2007 Jan 17;297(3):267-77
17227978
N Engl J Med. 2002 Apr 11;346(15):1128-37
11948273
J Clin Oncol. 2008 Jul 20;26(21):3503-10
18640931